Zymogenetics, Inc.

Hal Blumberg

Donald C Foster

Cindy A Sprecher

Darrell C Conklin

Stephen R Jaspers

Yasmin A Chandrasekher

Penny Thompson

Julia E Novak

Wenfeng Xu

Theresa A Deisher

James D Kelly

James L Holloway

Laura J Jelinek

Karen L Madden

Diane M Durnam

Maribeth A Eagan

Xu Wenfeng

Maribeth A Eagen

A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.

Method of treating rheumatoid arthritis using anti-IL-20 antibodies

Methods of treatment using anti-IL-20 antibodies

Method for treating inflammation

The present invention relates to polynucleotide and polypeptide molecules for z219c, a novel member of the human 2-19 protein family. The polypeptides, and polynucleotides encoding them, may be used for detecting various human disease states and chromosomal abnormalities. The present invention also includes antibodies to the z219c polypeptides.

Human 2-19 protein homologue z219C

Method for treating inflammation using soluble receptors to interleukin-20

The present invention relates to polynucleotide and polypeptide molecules for z219a, a novel member of the human 2-19 protein family. The polypeptides, and polynucleotides encoding them, may be used for detecting human chromosomal abnormalities. The present invention also includes antibodies to the z219a polypeptides.

Human 2-19 protein homologue, z219a

The present invention relates to ZPPAR4 polynucleotide molecules and ZPPAR4 polypeptide molecules. ZPPAR4 is a novel member of the nuclear receptor superfamily. The novel ZPPAR4 nuclear receptor can be used to examine ZPPAR4-related complex transcriptional networks and biological processes. The disclosed ZPPAR4 polynucleotides and polypeptides provide a means to identify the natural ligand for ZPPAR4, as well as agonists and antagonists thereof.

Nuclear receptor polypeptide ZPPAR4

Growing community of inventors

Seattle, WA, United States of America

Hal Blumberg